Multiple Myeloma
Multiple Myeloma
Advertisement
Cancer Nursing Today EditorsHematology & Blood Cancer | September 7, 2024
A study of more than 10,000 patients illuminated the characteristics and needs of patients who are in remission.
Read More
Cancer Nursing Today EditorsMultiple Myeloma | September 6, 2024
Learn how an innovative rehabilitation model improved clinical outcomes and patient satisfaction with nursing care.
Cancer Nursing Today EditorsMultiple Myeloma | September 5, 2024
Learn about the diverse unmet needs and potential solutions related to the experiences of patients and caregivers.
Cecilia BrownHematology & Blood Cancer | September 4, 2024
A subgroup analysis of CARTITUDE-4 evaluated ciltacabtagene autoleucel in functionally high-risk multiple myeloma.
Cecilia BrownHematology & Blood Cancer | September 3, 2024
The survey results will be used to formulate recommendations to improve patient involvement in decision making.
Cecilia BrownHematology & Blood Cancer | September 2, 2024
Nurses may be able to play a role in aligning views between patients and hematologists on prognosis and goals of care.
Amrita Krishnan, MDMultiple Myeloma | August 16, 2024
The approval is for induction and consolidation in patients with newly diagnosed multiple myeloma who are eligible for ASCT.
Cecilia BrownMultiple Myeloma | August 13, 2024
The approval is supported by data from the phase III PERSEUS study.
Salomon Manier, MD, PhDConferences | July 10, 2024
An expert shares his insights on the challenges and practical considerations that come with bispecific antibody treatment.
Elaine S. DeMeyer, RN, MSN, AOCN®, BMTCN®Multiple Myeloma | June 26, 2024
Currently, there is no standardization of melphalan administration.
Cecilia BrownConferences | June 14, 2024
A real-world study presented at the EHA 2024 Congress provided insights on patient and caregiver experiences.
Katie KoskoMultiple Myeloma | June 11, 2024
The risk of hospitalization was associated with the number of drugs in a patient's myeloma treatment regimen.
Elaine S. DeMeyer, RN, MSN, AOCN®, BMTCN®Multiple Myeloma | June 10, 2024
With 3 FDA-approved BiTEs for myeloma, oncology nurses must be able to understand BiTEs and explain them to patients.
Cecilia BrownMultiple Myeloma | May 23, 2024
Talquetamab is a T-cell redirecting bispecific antibody targeting GPRC5D on myeloma cells.
Cecilia BrownMultiple Myeloma | May 22, 2024
Due to the unique challenges associated with administering these therapies, a team aimed to standardize the workflow.
Elaine S. DeMeyer, RN, MSN, AOCN®, BMTCN®Multiple Myeloma | May 16, 2024
Misinformation or fake news can mislead patients with multiple myeloma.
Elaine S. DeMeyer, RN, MSN, AOCN®, BMTCN®Multiple Myeloma | May 14, 2024
Nurse researchers noted patients had “feelings of confusion at the time of initial diagnosis" of multiple myeloma.
Cecilia BrownConferences | June 5, 2024
The study showed that nursing support was a “key environmental facilitator" for physical activity in these patients.
Elaine S. DeMeyer, RN, MSN, AOCN®, BMTCN®Multiple Myeloma | April 19, 2024
Although CRAB describes end-organ symptoms of multiple myeloma, it does not provide a full picture.
Elaine S. DeMeyer, RN, MSN, AOCN®, BMTCN®Multiple Myeloma | April 8, 2024
Myeloma is a complex blood cancer that can be difficult to comprehend, especially the 2 earlier precursor disease stages.
Advertisement
Advertisement
Advertisement